5 years 1.17
Extreme 1.17
6.2
10 years 1.17
Extreme 1.17
43.2
Manager TitleAgeSince
Chief Operating Officer - 13/11/2022
Director TitleAgeSince
Director/Board Member 61 15/08/2005
Chairman 67 18/09/2014
Director/Board Member 55 04/06/2008
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.28M
-3.43%-6.07%+43.08%+63.81% 55.2B
+2.83%+0.48%+28.18%+82.59% 55.6B
-0.43%+0.66%-15.80%-14.88% 23.51B
-2.99%-6.94%-4.96%+352.51% 22.35B
-4.01%-3.67%+13.17%-14.29% 20.6B
-1.69%-3.89%+25.04%-34.34% 17.45B
-3.34%-7.77%+23.78%+536.66% 15.16B
-0.70%-1.72%+48.41%+177.50% 13.91B
-3.14%-8.47%+165.37%+292.18% 13.74B
Average -1.71%-1.27%+36.25%+160.19% 26.39B
Weighted average by Cap. -1.39%-0.52%+31.48%+123.66%
Logo 4SC AG
4Sc AG is a Germany-based clinical-stage biopharmaceutical company that develops small-molecule drugs that target key indications in cancer through epigenetic mechanisms. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
Employees
14